Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 109 or 20 × 10 9 per L

Transfusion

Volumn 47, Issue 9, 2007, Pages 1700-1709

  Nevo, Shoshan ^a,b   Fuller, Alice K ^b   Zahurak, Marianna L ^b   Hartley, Eric ^b   Borinsky, Mark E ^b   Vogelsang, Georgia B ^b  

^a Johns Hopkins University ^*  (Israel)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLEEDING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FATALITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; RISK FACTORS; SURVIVAL RATE; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548143392     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01345.x     Document Type: Article

References (57)

1. Platelet transfusion therapy, consensus conference. JAMA 1987 257 : 1777 80.
2. Pisciotto PT, Benson K, Hume H, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995 35 : 498 502.
3. Murphy MF. State of the art in platelet transfusion therapy. Transfus Sci 1997 17 : 575 84.
4. Patten E. Controversies in transfusion medicine. Prophylactic platelet transfusion revisited after 25 years: con. Transfusion 1992 32 : 381 5.
5. Baer MR, Bloomfield CD. Controversies in transfusion medicine. Prophylactic platelet transfusion therapy: pro. Transfusion 1992 32 : 377 80.
6. Beutler E. Platelet transfusions: the 20,000/microL trigger. Blood 1993 81 : 1411 3.
7. Kelleher JF. When to give platelet transfusions [letter]. Blood 1993 82 : 682.
8. Freireich EJ. When to give platelet transfusions [letter]. Blood 1993 82 : 682 3.
9. Finazzi G. Prophylactic platelet transfusion in acute leukemia: which threshold should be used. Haematologica 1998 83 : 961 2.
10. Ancliff PJ, Machin JS. Trigger factors for prophylactic platelet transfusion: consensus conference on platelet transfusion. Blood Rev 1998 12 : 234 8.
11. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999 6 : 437 41.
12. Benjamin RJ, Anderson KC. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? Crit Rev Oncol Hematol 2002 42 : 163 71.
13. Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol 2003 48 (Suppl S13 6.
14. Corash L. How much do we know about the platelet transfusion threshold? Transfusion 2003 43 : 691 3.
15. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996 18 : 931 5.
16. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns P. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997 15 : 1143 9.
17. Rebulla P, Finazzi G, Marangoni F, et al. A multicenter randomized study of the threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997 337 : 1870 5.
18. 9/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998 91 : 3601 6.
19. Navarro JT, Hernandez JA, Ribera JM, et al. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Haematologica 1998 83 : 998 1000.
20. Lawrence JB, Yomtovian RA, Hammons T, et al. Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma 2001 41 : 67 76.
21. Callow CR, Swindell R, Randall W, Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol 2002 118 : 677 82.
22. Zumberg MS, del Rosario ML, Nejame CF, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol Blood Marrow Transplant 2002 8 : 569 76.
23. Norfolk DR, Ancliffe PJ, Contreras M, et al. Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers. Br J Haematol 1998 101 : 609 17.
24. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 19 : 1519 38.
25. British committee for standards in haematology. Blood transfusion task force. Guidelines for the use of platelet transfusions. Br J Haematol 2003 122 : 10 23.
26. Nevo S, Enger C, Hartley E, et al. Acute bleeding and thrombocytopenia after bone marrow transplantation. Bone Marrow Transplant 2001 27 : 65 72.
27. First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood 1985 65 : 368 74.
28. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001 97 : 1219 26.
29. Nash RA, Gooley T, Davis C, Appelbaum FR. The problem of thrombocytopenia after hematopoietic stem cell transplantation. Oncologist 1996 1 : 371 80.
30. Dominietto A, Raiola AM, van Lint MT, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001 112 : 219 27.
31. Bruno B, Gooley T, Sullivian KM, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marow Transplant 2001 7 : 154 62.
32. Nevo S, Fuller AK, Hartley E, Borinsky ME, Vogelsang GB. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 × 10(9) and 20 × 10(9) per L. Transfusion 2007 47 : 801 12.
33. Nevo S, Swan V, Enger C, et al. Acute bleeding after BMT-incidence and effect on survival. A quantitative analysis in 1,402 patients. Blood 1998 91 : 1469 77.
34. Cox DR. The analysis of binary data. London : Methuen 1970.
35. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. JNCI 1959 22 : 719 48.
36. Robins JM, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse and large-strata limiting models. Biometrics 1986 42 : 311 23.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 53 : 457.
38. Cox DR. Regression models and life-tables (with discussion). J Roy Statist Soc B 1972 34 : 187 220.
39. SAS user's guide: statistics. Version 5 edition. Cary (NC) : SAS Institute Inc. 1985.
40. Miller CB, Piantadosi S, Vogelsang GB, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 1996 14 : 1327 32.
41. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 1989 73 : 1054 8.
42. Rio B, Andreu G, Nicod A, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986 67 : 1773 6.
43. Bick RL, Murano G. Physiology of hemostasis. Clin Lab Med 1994 14 : 677 707.
44. Body SC. Platelet activation and interactions with the microvasculature. J Cardiovasc Pharmacol 1996 27 (Suppl 1 S13 25.
45. Salat C, Holler E, Kolb HJ, Pinusch R, Reinhardt B, Hiller E. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant 1997 19 : 909 14.
46. Testa S, Manna A, Porcellini A, et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 1996 18 : 383 8.
47. Toda A, Takatsuka H, Nakajima T, et al. Serum elastase and antithrombin-3 in patients with acute graft-vs.-host disease after bone marrow transplantation. Clin Transplant 2005 19 : 466 9.
48. Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998 76 : 61 5.
49. Wadleigh M, Ho V, Momtaz P, Richardson P. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol 2003 10 : 451 62.
50. Takatsuka H, Wakae T, Mori A, et al. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003 31 : 475 9.
51. Wagner JL, Flowers ME, Longton G, Storb R, Martin P. Use of screening studies to predict survival among patients who do not have chronic graft-versus-host disease at day 100 after bone marrow transplantation [letter]. Biol Blood Marrow Transplant 2001 7 : 239 40.
52. Bolwell B, Pohlman B, Sobecks R, et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 2004 33 : 419 23.
53. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003 43 : 742 52.
54. Cook RJ, Heddle NM, Rebulla P, Sigouin CS, Webert KE. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion 2004 44 : 1135 42.
55. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF. Prophylactic platelet transfusion for hemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2004 18 : CD004269.
56. Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now? Br J Haematol 2005 131 : 588 95.
57. Gratwohl A, Tichelli A. Prophylactic platelet transfusions in acute myeloid leukemia. N Engl J Med 1998 338 : 1468.